Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 25, 2012

View Archived Issues

Promising nanoparticle-based dental treatment developed in Germany

Add-on apricoxib therapy may benefit subset of patients with pancreatic cancer

First HSP 90 inhibitor assessed in individuals with colorectal cancer

PI3K inhibitors active against gastrointestinal cancer cells

Ranbaxy Laboratories discloses novel 5-lipoxygenase inhibitors

Novel muscarinic acetylcholine M3 receptor antagonists presented

GlaxoSmithKline designs new bromodomain-containing protein inhibitors

Acura Pharmaceuticals provides Oxecta commercial update

Novel antiproliferative molecules patented at U.K. university

Belgian researchers disclose new protein kinase inhibitors

Aphios receives phase II SBIR grant to develop Alzheimer's disease therapy

Russian trial begins for Medistem's stem cell product for heart failure

Enlivex Therapeutics reports promising preliminary results in GVHD

Longitudinal data show applicability of florbetaben (18F) as a PET imaging agent in AD

NovaBay prepares to start phase IIb NVC-422 trial

Boehringer Ingelheim and Priaxon extend collaboration

Depomed starts new study of DM-1992

Almirall and BioFocus enter respiratory disease research alliance

Critical Outcome Technologies advances AML program

Johnson & Johnson highlights activities of fourth quarter 2011

Extended indication for Rebif approved in E.U.

Roche makes acquisition offer

NICE issues final guidance on Eliquis for VTE prevention in hip and knee surgery

Phase I/IIa trial launched of herbal product for Alzheimer's disease

Marina Biotech's START-FAP study advances to next stage

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...